Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Moon-Chang Baek's Biography

Moon-Chang Baek, Director, Exosome Convergence Research Center (ECRC), Kyungpook National University School of Medicine

Moon-Chang Baek received a Ph.D. in pharmacy at Seoul National University in 1997 and has held postdoctoral fellow positions in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (1998-2002) as well as in the Department of Life Science at POSTECH (2002-2005). He is currently a professor in the Department of Molecular Medicine at Kyungpook National University School of Medicine, Korea and a director of Exosome Convergence Research Center. His research interests have focused on the identification of exosomal protein biomarkers for diagnosis and prognosis of various cancers, mechanisms relating exosomes to cancer invasion, and development of new drugs targeted to the inhibition of exosome secretion.

Moon-Chang Baek Image

Inhibition of Exosome Secretion in Cancer Cells by an Antibiotic

Tuesday, 10 September 2019 at 14:00

Add to Calendar ▼2019-09-10 14:00:002019-09-10 15:00:00Europe/LondonInhibition of Exosome Secretion in Cancer Cells by an AntibioticCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul,

Inhibitors of the secretion of cancer exosomes, which promote cancer progression and metastasis, may not only accelerate exosome biology research but also offer therapeutic benefits for cancer patients. We identify sulfisoxazole (SFX) as an inhibitor of small extracellular vesicles (sEV) secretion from breast cancer cells through interference with endothelin receptor A (ETA). SFX, an FDA-approved oral antibiotic, showed significant anti-tumor and anti-metastatic effects in mouse models of breast cancer xenografts, reduced the expression of proteins involved in biogenesis and secretion of sEV, and triggered co-localization of multivesicular endosomes with lysosomes for degradation. The important role of ETA, as a newly-identified target of SFX, is demonstrated by gain- and loss-of-function studies of ETA protein through a direct binding assay, pharmacological and genetic approaches. These findings may provide a foundation for sEV-targeted cancer therapies and the mechanistic studies on sEV biology.

Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul,